2001

Rodriguez-Burford C, Chhieng DC, Stockard CR, Barnes MN, Alvarez RD, Partridge EE, Weiss HL, Grizzle WE: Association between p53 and ErbB-2 in primary and matached metastatic lesions of ovarian carcinoma. Abstract #1177, 92 nd Annual Meeting of the American Association for Cancer Research, New Orleans, LA, March 24-28, 2001.

Rodríguez-Burford C, Barnes MN , Berry W, Partridge EE, Grizzle WE: Immunohistochemical expression of molecular markers in an avian model: a potential model for pre-clinical evaluation of agents for ovarian cancer chemoprevention. Gynecology/Oncology 81:373-92001.

Meredith RF, Alvarez RD , Partridge EE, Khazaeli MB , Lin C-Y, Macey DJ, Austin JM, Kilgore LC, Russell CD, Grizzle WE, Schlom J, LoBuglio AF: Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm 16:305-15, 2001.

Meredith RF, Alvarez R, Partridge E, Khazaeli MB, Austin JM, Kilgore L, Grizzle WE, Schlom J, LoBuglio A: Phase I Studies of Combined Modality Intraperitoneal Therapy of Ovarian Cancer. Abstract #251, 92 nd Annual Meeting of the American Association for Cancer Research, New Orleans , LA , March 24 – 28, 2001.

Rodriguez-Burford C, Jones J, Partridge EE, Zhou T, Grizzle WE: The effects of a novel anti-human DR5 monoclonal antibody in ovarian carcinoma cells. Ninth annual SPORE Investigator's Workshop, July, 2001.

2002

Burford C, Barnes M, Oelschlager D, Myers R, Talley L, Partridge E, Grizzle W: Effects of non-steroidal anti-inflammatory agents (NSAIDS) on ovarian carcinoma cell lines: Preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 8:202-209, 2002.

Chhieng DC, Rodriguez-Burford C, Sviglin H, Talley LI, Stockard CR, Kleinberg MJ, Barnes MN, Partridge EE, Grizzle WE: Expression of CEA, Tag-72, and Lewis Y antigen in primary and metastatic lesions of ovarian carcinoma. 93 rd Annual Meeting of the American Association of Cancer Research, San Francisco , California April 6-10, 2002.

Chhieng DC , Rodriguez-Burford C, Stockard CR, Barnes MN , Sviglin H, Talley L, Alvarez RD , Partridge EE, Grizzle WE: Expression of therapeutic targets in primary matched metastatic lesions of ovarian carcinoma. 10 th SPORE Investigators' Workshop, Chantilly , Virginia , July 13-16, 2002.

Barnes MN , Grizzle WE, Grubbs CJ, Partridge EE: Paradigms for primary prevention of ovarian carcinoma. CA Cancer J Clin 52:216-225, 2002.

Barnes MN , Berry WD, Straughn JM, Kirby Tom, Leath CA , Huh WK, Grizzle WE: A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis. Gynecol Oncol 87:57-63, 2002.

Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF: A phase I study of combined modality (90) Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 8(9):2806-11, 2002.

Barnes MN , Berry WD, Straughn JM, Kirby TO, Leath CA , Huh WK, Grizzle WE, Edward PE: Utilization of a novel avian model of spontaneous ovarian carcinogenesis: results of a controlled trial of hormonal based chemoprevention. American Society of Clinical Oncology Annual Meeting, Orlando , FL , May 2002.

Chhieng DC , Rodriguez-Burford C, Stockard CR, Barnes MN , Sviglin H, Talley L, Alvarez RD , Partridge EE, Grizzle WE: Expression of therapeutic targets in primary matched metastatic lesions of ovarian carcinoma. 10 th SPORE Investigators' Workshop, Chantilly , Virginia , July 13-16, 2002. (Abstract #202).

2003

Rodriguez-Burford C, Oelschlager DK, Talley LI, Barnes MN , Partridge EE, Grizzle WE: The use of dimethyl sulfoxide (DMSO) as a vehicle in cull culture experiments using ovarian carcinoma cell lines. Biotechnic and Histochemistry 78:17-21, 2003.

Chhieng DC, Rodriguez-Burford C, Talley LI, Sviglin H, Stockard CR, Kleinberg MJ, Barnes MN, Partridge EE, Khazaeli MB, Grizzle WE: Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma. Hum Pathol 34(10):1016-21, 2003.

Rodriguez-Burford C, Chhieng DC , Stockard CR, Kleinberg MJ, Barnes MN , Partridge EE, Weiss HL, Grizzle WE: P53 and erbB-2 are not associated in matched cases of primary and metastatic ovarian carcinomas. Dis Markers 19(1):11-17, 2003.

Jones J, Rodriguez-Burford C, Zhou T, Tousson A, Grizzle WE: Phenotypic expression of the TRAIL receptors, DR4 and DR5, in cell lines and tissues of adenocarcinomas of the ovary. Presented at the 11 th SPORE Investigators' Workshop, July 8-10, 2003, Baltimore , MD.

Miller EJ, Suarez-Cuervo C, Singh RS, Vital-Reyes V, Barnes III, MN, Grizzle WE: Effects of celebrex in ovarian carcinoma cell lines. Presented at the 11 th SPORE Investigators' Workshop, July 8-10, 2003, Baltimore , MD.

Barnes NM , Chieng D, Miller E, Grizzle WE, Jones L, Partridge EE: A controlled clinical trial of celecoxib as a chemopreventive agent in women at elevated risk of ovarian carcinoma: Evaluation of enrollment into a pilot study. Presented at the 11 th SPORE Investigators' Workshop, July 8-10, 2003, Baltimore , MD.

Jones J, Zhou T, Tousson A, Rodriguez-Burford C, Grizzle WE: The pattern of expression of TRAIL receptors, DR4 and DR5, in ovarian neoplasia. Presented at the American Association for Cancer Research 94 th Annual Meeting, July 2003, Washington , DC . Abstract #2185.

Gaines J, Bhoola SM, Straughn JM, Grizzle W, Strong TV, Shaw DR: Expression of sperm protein 17 (Sp17) in ovarian tumors. Presented at the American Association for Cancer Research 94 th Annual Meeting, July 2003, Washington , DC . Abstract #1859.

McDuffee E, Thornthwaite JT, Bates J, Stockard CR, Grizzle W: Immunostaining of a newly identified cancer antigen present in cell membranes of ovarian carcinoma tissues. Presented at the AACR “Frontiers in Cancer Prevention Research” meeting, October 26-30, 2003, Phoenix , AZ.

Vital-Reyes V, Miller EJ, Rodriguez-Burford C, Suarez-Cuervo C, Singh RS, Barnes MN , Grizzle WE: Effects of celebrex on ovarian carcinoma cell lines. Presented at the AACR “Frontiers in Cancer Prevention Research” meeting, October 26-30, 2003, Phoenix , AZ.

2004

Straughn JM Jr, Shaw DR, Guerrero A, Bhoola SM, Racelis A, Wang Z, Chiriva-Internati M, Grizzle WE, Alvarez RD, Lim SH, Strong TV: Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 108(6)805-11, 2004.

McDuffee EC, Thornthwaite JT, Jones JL, Rodriguez-Burford C, Grizzle WE: The expression of LT-11 in ovarian carcinoma and normal ovarian tissues. Abstract #5471. Presented at the American Association for Cancer Research 95 th Annual Meeting, Orlando , Florida , March 27-31, 2004.

Vital-Reyes V, Rodriguez-Burford C, Oelschlager DK, Suarez-Cuervo C, Manne U, Grizzle WE: COX-2 inhibitor (Celecoxib) affects the cellular growth and phenotypic expression of p53 in only selected colon, prostate and ovarian cancer cell lines. Abstract #4391. Presented at the American Association for Cancer Research 95 th Annual Meeting, Orlando , Florida , March 27-31, 2004.

Vital-Reyes V, Rodriguez-Burford C, Oelschlager DK, Suarez-Cuervo C, Manne U, Grizzle, WE: The COX-2 inhibitor, Celecoxib, inhibits differentially the cellular growth of ovarian, prostate and colon carcinoma cell lines independent of p53 status. Presented at the 12 th SPORE Investigators' Workshop, Baltimore , MD , July 10-13, 2004.

Barnes MN , Chhieng D, Jones J, Riaz V, Dreher M, Grizzle WE, Jones L, Talley L, Partridge EE: A controlled clinical trial of Celecoxib as a chemopreventive agent for ovarian cancer: a feasibility study in women at elevated risk. Presented at the 12 th SPORE Investigators' Workshop, Baltimore , MD , July 10-13, 2004.

Vital-Reyes V, Rodriguez-Burford, Oelschlager KD, Suarez-Cuervo C, Manne U, Grizzle WE: The COX-2 inhibitor, celecoxib, inhibits differentially the cellular growth of ovarian, prostate and colon carcinoma cell lines independent of p53 status. Abstract # 508. Presented at the Third Annual AACR International Conference “Frontiers in Cancer Prevention Research” meeting, Seattle , WA , October 16-20, 2004.